Obinutuzumab
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Explore 105 assets in Relapsed/Refractory Diffuse Large B-Cell Lymphoma →Floatz Rating
B58/100
Confidence
Indicative
Sponsor
Olivia Newton-John Cancer Research Institute
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07634289CT.gov Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse Large B Cell Lymphoma | — | Not Yet Recruiting | — | — | — |
NCT07387848CT.gov Glofitamab as a Bridge to and/or Consolidation Post Autologous Stem Cell Transplant in Patients With Relapsed B Cell Lymphomas | — | Not Yet Recruiting | — | — | — |
NCT07480850CT.gov Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT06649812CT.gov Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma | — | Recruiting | — | — | — |
NCT06570447CT.gov Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL | — | Recruiting | — | — | — |
NCT06867536CT.gov Hypofractionation Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse B-cell Lymphoma With Baseline High Tumor Burden | — | Recruiting | — | — | — |
NCT04703686CT.gov Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy | — | Completed | — | — | — |
NCT03401853CT.gov Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma | — | Terminated | — | — | — |
NCT02992522CT.gov Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Relapsed/Refractory Diffuse Large B-Cell Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Obinutuzumab (this asset) | Olivia Newton-John Cancer Research Institute | P2 | B · 58 |
| Selinexor | Chengdu Zenitar Biomedical Technology Co., Ltd | P3 | BB |
| Dexasone | City of Hope Medical Center | P2/3 | BB |
| Etoposide | University of California, Davis | P3 | BB |
| Axicabtagene Ciloleucel | Zhujiang Hospital | P3 | BB |
| Cyclophosphamide | Nathan Denlinger | P3 | BB |
| Isocyclophosphamide | University of California, Davis | P3 | BB |
| Prednisone | National Cancer Institute (NCI) | P3 | BB |
| Cytarabine | City of Hope Medical Center | P3 | BB |
+42 more in the Relapsed/Refractory Diffuse Large B-Cell Lymphoma cohort
Other indications for Obinutuzumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Richter Transformation | — | P2 | BB · 71 |
| B-Cell Chronic Lymphocytic Leukemia | — | P3 | BB · 71 |
| Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | — | P3 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Obinutuzumab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/obinutuzumab-relapsedrefractory-diffuse-large-b-cell-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →